Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
about
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancerALDH1 expression correlates with favorable prognosis in ovarian cancersPaclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentEstablishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumorsPre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group studyThe induction of the apoptosis of cancer cell by sonodynamic therapy: a review.Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome.Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experienceRadiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment.Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.Scope of nanotechnology in ovarian cancer therapeutics.Pegylated liposomal doxorubicin in the management of ovarian cancerEnhancing chemotherapy response with Bmi-1 silencing in ovarian cancerA multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancerCost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testingTrabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancerEmerging role of pemetrexed in ovarian cancer.Prediction of resistance to chemotherapy in ovarian cancer: a systematic review.Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic reviewProgression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.Quality of life in patients receiving treatment for gynecologic malignancies: special considerations for patient care.Ovarian cancer: opportunity for targeted therapy.Episensitization: Defying Time's ArrowRelationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancerContemporary quality of life issues affecting gynecologic cancer survivors.Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian PopulationEnhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin.Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France.Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery.Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence
P2860
Q24632636-E03E6417-18EE-4332-B83C-034E9B0CBD85Q24649718-54672115-1599-4F3F-80F1-A45539F0CD0AQ28073057-3D497A54-8020-4DA5-8F02-DB2751888605Q28485444-AAFDD5B8-CCC6-49AF-9481-DD79AD5E6C26Q30419554-D061ABE8-399B-450D-810C-962FAE45C334Q30458879-63531535-87FD-4A49-B365-BB4F0D09EF7AQ33379265-7CF3B171-EBE7-48FB-B701-42646B1D29EFQ33387755-EE2E7EFF-82A8-455F-920D-B92C10466F1EQ33392472-10C275FA-9DAA-4990-B176-CC18C1839038Q33858199-E2962DDE-9630-478F-961A-ADEFF89E55F7Q33892483-1E2E6D5E-4F63-43E9-ABD4-72199E837864Q33899157-CF77882B-2888-464B-A42F-654BA058A777Q33919697-CEAA36F2-97B7-4A7D-AB5A-45EB17EBAB28Q33959550-1E4CB84F-9F48-4164-AA72-224F8396EE53Q34075216-4A68B71B-29BD-4401-AC21-78EC26C840D4Q34187661-223018E6-A173-4D0D-A7DF-1A9F6D1E3D79Q34704011-08098F96-46FC-4175-B659-31DF8A274A47Q34967545-2985096F-880B-4191-9EA5-667DA598B864Q34994574-57F0B81D-EFC2-4D1D-80D3-40CEA12EE8BBQ34996149-EB70657C-9C9B-4608-B14F-F1484001EAC8Q35015611-4C4A0372-B126-4A48-BEC9-6E81418AABDCQ35212386-80210391-31E3-45F5-A3B9-F4A0405E2A7DQ35235675-91401315-F339-43A7-989B-B9FD3D92C6A9Q35583734-6DCF1518-21A9-4E45-B56E-A43FCB42C0B3Q35632548-A89CADDF-C0E9-4DA2-A229-0DC58A3F5275Q35648863-DEBBFCC5-FD6F-44EF-B810-02690963957AQ35659945-16042EFA-A3D5-44AE-A720-72640B206D39Q35726218-F1D3D226-8EF7-4C6B-B7F6-0D048978AA6DQ35730375-DA89DCE5-7DF5-492F-A0BB-E5600BEBD7F4Q36067725-EC4D4B3F-CFE5-45D6-B2BF-15155F24CE7CQ36076868-9667BF80-37FD-47D0-B7D7-74828E4B102FQ36148627-911B7B6A-0C24-4B55-B442-2CAA6C70E8F9Q36239919-99ABDD03-4243-4AD5-BE5C-744584CE64DAQ36240562-6D8A2377-1B59-4629-AC29-01A94E84D785Q36413165-1262FEF1-1992-4852-A187-076EFDCE88BDQ36413483-4DE47B7B-DF6C-45C1-8E29-0C078CC39414Q36463830-D4E8DE33-8ABB-441D-993B-11AAC4A3BE59Q36621252-A68D15DE-E28E-49CA-8C7B-F17D5322C8E9Q36642134-1C6200F8-80CD-4424-AFE2-8B37A494E991Q36654413-73C9EA9C-925D-4836-9DF0-FB2EE89F7409
P2860
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@ast
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@en
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@nl
type
label
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@ast
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@en
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@nl
prefLabel
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@ast
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@en
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@nl
P1433
P1476
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
@en
P2093
Deborah K Armstrong
P356
10.1634/THEONCOLOGIST.7-SUPPL_5-20
P478
P577
2002-01-01T00:00:00Z